Literature DB >> 22390490

Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies.

Robert Chiesa1, Paul Veys.   

Abstract

Conventional myeloablative conditioning regimens prior to hematopoietic cell transplantation (HCT) are associated with significant transplant-related morbidity and mortality in children affected by primary immunodeficiency disorders. Reduced-intensity conditioning regimens have been extensively used without severe acute toxicity in patients with pre-HCT comorbidities, with the additional advantage of reducing or avoiding long-term sequelae such as infertility and growth retardation. Compared with myeloablative HCT, reduced-intensity conditioning regimens are associated with an increased incidence of mixed donor chimerism and graft rejection. While mixed donor engraftment is likely to correct the phenotypic expression of most children with primary immunodeficiency disorders, the use of donor lymphocyte infusion to increase donor chimerism or second HCT procedures may be required in some cases. Here we discuss the most recent data on the use of different reduced-intensity conditioning protocols in children with primary immunodeficiency disorders, highlighting significant clinical lessons and areas that need additional study.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22390490     DOI: 10.1586/eci.12.9

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  15 in total

1.  A Stable Mixed Chimera After SCT with RIC in an Infant with IκBα Hypermorphic Mutation.

Authors:  Masayuki Nagasawa; Teppei Ohkawa; Masatoshi Takagi; Kohsuke Imai; Tomohiro Morio
Journal:  J Clin Immunol       Date:  2017-02-21       Impact factor: 8.317

Review 2.  Long-term management of leukocyte adhesion deficiency type III without hematopoietic stem cell transplantation.

Authors:  Paul Saultier; Sarah Szepetowski; Matthias Canault; Céline Falaise; Marjorie Poggi; Pierre Suchon; Vincent Barlogis; Gérard Michel; Stéphane Loyau; Martine Jandrot-Perrus; Jean-Claude Bordet; Marie-Christine Alessi; Hervé Chambost
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

Review 3.  Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases.

Authors:  Katsutsugu Umeda
Journal:  Int J Hematol       Date:  2022-05-14       Impact factor: 2.490

4.  Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.

Authors:  A A Hamidieh; M Behfar; Z Pourpak; S Faghihi-Kashani; M R Fazlollahi; A S Hosseini; M Movahedi; M Mozafari; M Moin; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

5.  The role of Tα1 on the infective patients after hematopoietic stem cell transplantation.

Authors:  Jia-Hua Ding; Lin-Lin Wang; Zhi Chen; Jun Wang; Zheng-Ping Yu; Gang Zhao; Bao-An Chen
Journal:  Int J Hematol       Date:  2013-01-10       Impact factor: 2.490

6.  Primary Immune Deficiency Treatment Consortium (PIDTC) report.

Authors:  Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Donald B Kohn; Jennifer M Puck; Sung-Yun Pai; Barbara Ballard; Sarah C Bauer; Jack J H Bleesing; Marcia Boyle; Amy Brower; Rebecca H Buckley; Mirjam van der Burg; Lauri M Burroughs; Fabio Candotti; Andrew J Cant; Talal Chatila; Charlotte Cunningham-Rundles; Mary C Dinauer; Christopher C Dvorak; Alexandra H Filipovich; Thomas A Fleisher; Hubert Bobby Gaspar; Tayfun Gungor; Elie Haddad; Emily Hovermale; Faith Huang; Alan Hurley; Mary Hurley; Sumathi Iyengar; Elizabeth M Kang; Brent R Logan; Janel R Long-Boyle; Harry L Malech; Sean A McGhee; Fred Modell; Vicki Modell; Hans D Ochs; Richard J O'Reilly; Robertson Parkman; David J Rawlings; John M Routes; William T Shearer; Trudy N Small; Heather Smith; Kathleen E Sullivan; Paul Szabolcs; Adrian Thrasher; Troy R Torgerson; Paul Veys; Kenneth Weinberg; Juan Carlos Zuniga-Pflucker
Journal:  J Allergy Clin Immunol       Date:  2013-10-15       Impact factor: 10.793

7.  Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.

Authors:  Beatriz Morillo-Gutierrez; Rita Beier; Kanchan Rao; Lauri Burroughs; Ansgar Schulz; Anna-Maria Ewins; Brenda Gibson; Petr Sedlacek; Ladislav Krol; Brigitte Strahm; Irina Zaidman; Krzysztof Kalwak; Julie-An Talano; Ann Woolfrey; Chris Fraser; Isabelle Meyts; Ingo Müller; Jacek Wachowiak; Maria Ester Bernardo; Paul Veys; Karl-Walter Sykora; Andrew R Gennery; Mary Slatter
Journal:  Blood       Date:  2016-05-23       Impact factor: 22.113

8.  Anti-Müllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens.

Authors:  Alison Leiper; Maite Houwing; E Graham Davies; Kanchan Rao; Siobhan Burns; Emma Morris; Joop Laven; Anne-Lotte van der Kooi; Marry van den Heuvel Eibrink; Stephen Nussey
Journal:  Bone Marrow Transplant       Date:  2020-03-30       Impact factor: 5.483

9.  Experience with a Reduced Toxicity Allogeneic Transplant Regimen for Non-CGD Primary Immune Deficiencies Requiring Myeloablation.

Authors:  Sharat Chandra; Shanmuganathan Chandrakasan; Pooja Khandelwal; Rebecca A Marsh; Blachy J Dávila Saldaña; Jack J Bleesing; Michael B Jordan; Ashish R Kumar; Michael S Grimley; Christa Krupski; Stella M Davies
Journal:  J Clin Immunol       Date:  2020-10-16       Impact factor: 8.317

10.  Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes.

Authors:  Gabriela Llaurador; Eileen Nicoletti; Susan E Prockop; Susan Hsu; Kirsten Fuller; Audrey Mauguen; Richard J O'Reilly; Jaap J Boelens; Farid Boulad
Journal:  Transplant Cell Ther       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.